AI-powered diagnostic and surgical planning software platformToday, 150M+ people are suffering from a brain aneurysm globally. Each year 500K people die because of strokes which, in most cases, are caused by aneurysm. VasoGnosis's mission is to save brains – so people can keep living independently. Our AI-powered diagnostic and surgical planning software as a service (SaaS) for cerebrovascular diseases, helps neurosurgeons and interventional neuroradiologists make data-driven decisions. VasoGnosis's predictive analytics powered by Big-Data will substantiate the need for life-dependent surgeries that would otherwise be unsupported. To demonstrate clinical relevance and establish commercial relationships, VasoGnosis has entered functional agreements with medical institutions like UMass Memor... [Read More]
A Crowd Note modifies the typical convertible note so that the crowd does not automatically convert to equity shareholders.
June 22, 2020
August 14, 2020
Open to Investors
Research & Development, Regulation Filing
Co-founder and Chief Executive Officer
Ali holds a PhD in Mechanical Engineering from University of Wisconsin Milwaukee, USA. He is passionate about fluid dynamics and machine learning with applications to healthcare and blood flow models.Prior to Ali founding VasoGnosis in 2019, he was a postdoc researcher at the neurosurgery department of Medical College of Wisconsin performing research on brain aneurysm. Before immigrating to the USA in 2014, Ali founded two other IT companies.
Co-founder and Chief Technology Officer
Pedram Ghamisi, a senior member of IEEE, graduated with a Ph.D. in electrical and computer engineering at the University of Iceland in 2015. He works as the head of the machine learning group at Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Germany and as the CTO and co-founder of VasoGnosis Inc, USA. He is also the co-chair of IEEE Image Analysis and Data Fusion Committee. Dr. Ghamisi has won several awards mostly on the topics of machine (deep) learning and multi-sensor data fusion and his papers have been frequently recognized as the most popular ones published by IEEE Geoscience and Remote Sensing journals. For detailed info, please see http://pedram-ghamisi.com/.
Chief Medical Officer
Sundeep Mangla, M.D., is a Clinical and Research Expert in Interventional Neuroradiology and Endovascular Neurosurgery, focusing on advancing diagnosis and treatment of complex cerebrovascular diseases. After completing his training at NEOMED, USC, Yale, and University of Iowa (1992-2000), Dr. Mangla has served as attending faculty at Columbia, Cornell, SUNY, NYU, and Mount Sinai in New York having performed several thousand neurovascular interventions for brain aneurysms, ischemic, and hemorrhagic stroke from 2000-2020. Dr. Mangla has extensive record of peer-reviewed publications, international presentations of original basic science and clinical research (Neuroimaging, Stroke Intervention, Aneurysm Therapy), clinical trials (ARUBA, MERCI, TEAM), and novel biomedical diagnostic and therapeutic tool development and testing (Animal Models, Brain Hypothermia, Ischemic Stroke Imaging, Nano-engineering) for management of cerebrovascular disease patients. He has extensive experience collaborating with the medical device industry, developing and testing new products, and joined the Vasognosis team as CMO in 2019.
Co-founder and Chief Operation Officer
Alexa is a multi-talented engineer with experience in software, hardware, fluid dynamics, and rapid physical prototyping. She received her degree in mechanical engineering from the University of Wisconsin - Milwaukee, and has a further 10 years of experience with coding and data analysis. She thrives on large solution-spaces and fast-paced development environments, and excels at creating minimum viable products to test out new ideas.
Round type: Seed Round size: US $600,000 Minimum investment: US $1,000 Target Minimum: US $500,000 Security Type: Crowd Note Conversion discount: 20.0% Interest rate: 5.0% Note term: 24 months
There are no additional research reports currently.